Compare General Mills, Inc. (GIS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? General Mills, Inc. trades at $32.43 (market cap $17.43B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: General Mills, Inc. is far larger — about 8.1× Recursion Pharmaceuticals Inc's market cap, and General Mills, Inc. pays a 7.49% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GIS | RXRX | |
|---|---|---|
Market Cap | $17.43B | $2.14B |
Volume | 16,554,362 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $6.79 |
52-Week Low | $31.67 | $2.84 |
Typical Hold Time | 106 Days | 22 Days |
Enterprise Value | $30.61B | $1.66B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.77, down 1.27% on the day, with a bearish technical signal and mixed earnings performance. The stock shows attractive valuation ratios like a P/E of 9.23 and P/S of 0.93, but profitability metrics are weak with a negative net income margin and ROE. Recent news highlights a CEO transition and a 22% stock decline last month amid revenue and profit pressures.
The outlook is cautious; while the dividend yield is appealing and cost-saving initiatives are in place, declining revenue, margin compression, and high debt levels pose significant risks. Analyst consensus is mixed with a $36 price target, but bearish sentiment and competitive pressures suggest limited near-term upside.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
